Warsaw, Poland Clinical Trials

A listing of Warsaw, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 555 clinical trials
Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All …

cholestatic pruritus
cholangitis
GSK Investigational Site
 (1.6 away) Contact site
  • 39 views
  • 15 Jul, 2022
  • +27 other locations
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

deficiency
21-ohd
Neurocrine Clinical Site
 (4.6 away) Contact site
  • 123 views
  • 27 Apr, 2022
  • +55 other locations
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).

Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
 (2.6 away) Contact site
  • 0 views
  • 21 Jul, 2022
  • +67 other locations
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Galderma Investigational Site
 (4.2 away) Contact site
  • 42 views
  • 09 Jul, 2022
  • +83 other locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

lung carcinoma
growth factor
epidermal growth factor receptor
carboplatin
cancer chemotherapy
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
 (5.6 away) Contact site
  • 37 views
  • 21 Jul, 2022
  • +207 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o.
 (3.0 away) Contact site
  • 87 views
  • 29 Jul, 2022
  • +315 other locations
An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis

The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.

Galderma Investigational Site
 (3.9 away) Contact site
  • 59 views
  • 08 Jul, 2022
  • +81 other locations
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

This study aims to define the efficacy and safety of inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD).

Viela Bio Investigative Site
 (186.3 away) Contact site
  • 1 views
  • 23 Apr, 2022
  • +70 other locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.

Research Site
 (6.0 away) Contact site
  • 1 views
  • 12 Jul, 2022
  • +16 other locations
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of …

Szpital Grochowski im. dr.med. Rafala Masztaka
 (3.0 away) Contact site
  • 17 views
  • 13 Jul, 2022
  • +84 other locations